Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C5AR1 | P21730 | 5/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.38 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.37 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18179635 | 0.86 | SIGMAR1 (0.42) | TSHRSIGMAR1 | |
| Hydrochloric Acid SCHEMBL28473625 | 0.82 | SIGMAR1 (0.39) | TSHRP2RX7SIGMAR1 | |
| SCHEMBL18179627 | 0.82 | DDB1 (0.43) | C5AR1ALOX15P2RX7DDB1CRBN | |
| SCHEMBL18179628 | 0.82 | P2RX7 (0.40) | C5AR1ALDH1A1ALOX15TSHRP2RX7 | |
| SCHEMBL8873384 | 0.82 | SIGMAR1 (0.50) | ALDH1A1P2RX7DDB1CRBNSIGMAR1 | |
| SCHEMBL16834193 | 0.82 | ATM (0.40) | C5AR1ALDH1A1SIGMAR1ADRB1 | |
| SCHEMBL28473624 | 0.80 | SIGMAR1 (0.37) | TSHRP2RX7SIGMAR1 | |
| SCHEMBL18179626 | 0.77 | DDB1 (0.40) | ALDH1A1P2RX7DDB1CRBNSIGMAR1 | |
| SCHEMBL6289904 | 0.73 | SIGMAR1 (0.46) | ALDH1A1P2RX7SIGMAR1 | |
| Hydrochloric Acid SCHEMBL1609149 | 0.73 | ADRB1 (0.44) | C5AR1ALDH1A1ALOX15TSHRADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9862734-B2 | Metal-ligand complex, olefin polymerization catalyst derived therefrom, and olefin polymerization method utilizing the catalyst | DOW GLOBAL TECHNOLOGIES LLC (US) | 2018-01-09 | — | — | US | disclosed |
| US-20160311837-A1 | METAL-LIGAND COMPLEX, OLEFIN POLYMERIZATION CATALYST DERIVED THEREFROM, AND OLEFIN POLYMERIZATION METHOD UTILIZING THE CATALYST | DOW GLOBAL TECHNOLOGIES LLC | 2016-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160311837-A1 | METAL-LIGAND COMPLEX, OLEFIN POLYMERIZATION CATALYST DERIVED THEREFROM, AND OLEFIN POLYMERIZATION METHOD UTILIZING THE CATALYST | OPRM1, WASF2, WEE1 | C5AR1 2005/4885ALDH1A1 2447/4885ALOX15 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.